Algenpantucel-L

01/01/2016 - "Pancreatic cancer: Update on immunotherapies and algenpantucel-L."
01/01/2013 - "The addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve survival. "
01/01/2013 - "Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study."
01/01/2022 - "A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer."
02/01/2016 - "Here, we report preliminary results and biomarkers correlations with clinical activity of algenpantucel-L in pancreatic cancer."

03/09/2011 - "A phase II study was presented at the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium to assess the effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer (Abstract #236). "

02/01/2016 - "Algenpantucel-L immunotherapy in pancreatic adenocarcinoma."
01/01/2022 - "To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy alone in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). "

02/01/2016 - "Algenpantucel-L (HyperAcute Pancreas, NewLink Genetics, Ames, IA, USA) is a whole-cell immunotherapy consisting of irradiated allogeneic pancreatic cancer cells genetically engineered to express the murine enzyme α-GT, which results in hyperacute rejection of the tumor cells with complement- and antibody-dependent cytotoxicity. "